Pacer Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Pacer Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53K	Sell	436 -4,480	-91%	-$468K	﹤0.01%	2025
2026 Q1	$518K	Buy	+4,916	New	+$435K	﹤0.01%	1479
2025 Q1	–	Sell	-1,876,466	Closed	-$72.4M	–	3759
2024 Q4	$72.4M	Buy	1,876,466 +142,376	+8%	+$6.21M	0.16%	153
2024 Q3	$78M	Buy	1,734,090 +1,733,662	+405,061%	+$70M	0.16%	151
2024 Q2	$14.8K	Sell	428 -685	-62%	-$20.1K	﹤0.01%	3486
2024 Q1	$32.2K	Buy	+1,113	New	+$30.3K	﹤0.01%	3339
2021 Q2	–	Sell	-1,780	Closed	-$46K	–	1519
2021 Q1	$46K	Sell	1,780 -178	-9%	-$4.5K	﹤0.01%	1448
2020 Q4	$39K	Buy	+1,958	New	+$42.1K	﹤0.01%	1438

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pacer Advisors's PTGX Position: Q2 2026 in Review

Pacer Advisors reduced its Protagonist Therapeutics (PTGX) stake by 91% in Q2 2026, selling an estimated $468K and leaving 436 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

Pacer Advisors first reported a position in PTGX in Q4 2020 and has held it in 8 quarters since. The position peaked at $78M in Q3 2024. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Pacer Advisors held 436 shares of Protagonist Therapeutics worth $53K as of Q2 2026.
Pacer Advisors sold 4,480 Protagonist Therapeutics shares in Q2 2026, an estimated $468K.
Protagonist Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2025 holding.
Pacer Advisors first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 8 quarters since.
Pacer Advisors's Protagonist Therapeutics position peaked at $78M in Q3 2024.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.